LivaNova (LIVN) Free Cash Flow Growth (3y) (2019 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 6.28% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 9.63% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 22.80% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 29.36% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -27.72% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -0.27% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 77.20% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -20.37% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 19.32% |
| 10 | LivaNova | 4.03 Bn | 3.45 Bn | 243.75 Mn | -58.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -58.62% |
| Dec 31, 2025 | 73.72% |
| Sep 30, 2025 | 28.07% |
| Jun 30, 2025 | 70.06% |
| Mar 31, 2025 | -13.85% |
| Dec 31, 2024 | 38.17% |
| Sep 30, 2024 | 16.67% |
| Jun 30, 2024 | 17.51% |
| Mar 31, 2024 | -31.73% |
| Dec 31, 2023 | 10.51% |
| Sep 30, 2023 | 92.54% |
| Jun 30, 2023 | 5.96% |
| Mar 31, 2023 | 28.34% |
| Dec 31, 2022 | 57.47% |
| Sep 30, 2022 | 33.11% |
| Jun 30, 2022 | 12.52% |
| Mar 31, 2022 | 95.49% |
| Dec 31, 2021 | 47.80% |
| Sep 30, 2021 | -19.22% |
| Jun 30, 2021 | -3.66% |
| Mar 31, 2021 | -8.18% |
| Dec 31, 2020 | 51.50% |
| Sep 30, 2020 | -27.15% |
| Jun 30, 2020 | -46.61% |
| Mar 31, 2020 | -86.35% |
| Dec 31, 2019 | -29.27% |
| Sep 30, 2019 | -75.14% |
| Mar 31, 2019 | -66.01% |